BR112013023298A2 - uso de uma composição na fabricação de um produto para a prevenção ou tratamento de neurotrauma, lesão cerebral traumática, paralisia cerebral e lesão da coluna vertebral e uso de um kit de partes na fabricação de um produto para a prevenção ou tratamento de neurotrauma, lesão cerebral traumática, paralisia cerebral e lesão da coluna vertebral - Google Patents
uso de uma composição na fabricação de um produto para a prevenção ou tratamento de neurotrauma, lesão cerebral traumática, paralisia cerebral e lesão da coluna vertebral e uso de um kit de partes na fabricação de um produto para a prevenção ou tratamento de neurotrauma, lesão cerebral traumática, paralisia cerebral e lesão da coluna vertebralInfo
- Publication number
- BR112013023298A2 BR112013023298A2 BR112013023298A BR112013023298A BR112013023298A2 BR 112013023298 A2 BR112013023298 A2 BR 112013023298A2 BR 112013023298 A BR112013023298 A BR 112013023298A BR 112013023298 A BR112013023298 A BR 112013023298A BR 112013023298 A2 BR112013023298 A2 BR 112013023298A2
- Authority
- BR
- Brazil
- Prior art keywords
- neurotrauma
- prevention
- manufacture
- treatment
- injury
- Prior art date
Links
- 208000020339 Spinal injury Diseases 0.000 title 2
- 206010008129 cerebral palsy Diseases 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 2
- 230000002265 prevention Effects 0.000 title 2
- 208000030886 Traumatic Brain injury Diseases 0.000 title 1
- 208000029028 brain injury Diseases 0.000 title 1
- 208000014674 injury Diseases 0.000 title 1
- 230000008733 trauma Effects 0.000 title 1
- 230000009529 traumatic brain injury Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/003—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0053—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122020000836-9A BR122020000836B1 (pt) | 2011-03-14 | 2012-03-14 | Uso de uma composição na fabricação de um produto para a prevenção ou tratamento de lesão cerebral traumática ou paralisia cerebral, e uso de um kit de partes na fabricação de um produto para a prevenção ou tratamento de lesão cerebral traumática ou paralisia cerebral |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NLPCT/NL2011/050176 | 2011-03-14 | ||
PCT/NL2011/050176 WO2012125020A1 (en) | 2011-03-14 | 2011-03-14 | Method for treating neurotrauma |
PCT/NL2012/050158 WO2012125034A1 (en) | 2011-03-14 | 2012-03-14 | Method for treating neurotrauma |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013023298A2 true BR112013023298A2 (pt) | 2017-02-07 |
BR112013023298B1 BR112013023298B1 (pt) | 2020-09-01 |
Family
ID=45928978
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013023298-6A BR112013023298B1 (pt) | 2011-03-14 | 2012-03-14 | Uso de uma composição na fabricação de um produto para a prevenção ou tratamento de lesão da coluna vertebral e uso de um kit de partes na fabricação de um produto para a prevenção ou tratamento de lesão da coluna vertebral |
BR122020000836-9A BR122020000836B1 (pt) | 2011-03-14 | 2012-03-14 | Uso de uma composição na fabricação de um produto para a prevenção ou tratamento de lesão cerebral traumática ou paralisia cerebral, e uso de um kit de partes na fabricação de um produto para a prevenção ou tratamento de lesão cerebral traumática ou paralisia cerebral |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122020000836-9A BR122020000836B1 (pt) | 2011-03-14 | 2012-03-14 | Uso de uma composição na fabricação de um produto para a prevenção ou tratamento de lesão cerebral traumática ou paralisia cerebral, e uso de um kit de partes na fabricação de um produto para a prevenção ou tratamento de lesão cerebral traumática ou paralisia cerebral |
Country Status (12)
Country | Link |
---|---|
US (2) | US9579336B2 (pt) |
EP (2) | EP2685961B1 (pt) |
JP (2) | JP6022488B2 (pt) |
CN (2) | CN106902104A (pt) |
AU (2) | AU2012229649B2 (pt) |
BR (2) | BR112013023298B1 (pt) |
CA (1) | CA2830165C (pt) |
ES (1) | ES2687445T3 (pt) |
MX (2) | MX355035B (pt) |
PL (1) | PL2685961T3 (pt) |
RU (2) | RU2749191C2 (pt) |
WO (2) | WO2012125020A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150044138A1 (en) * | 2012-03-02 | 2015-02-12 | N.V. Nutricia | Method for improving functional synaptic connectivity |
CN102823778B (zh) * | 2012-09-24 | 2013-06-26 | 吴江市田宇生物科技有限公司 | 一种实验小型猪专用功能性饲料添加剂 |
US20140199265A1 (en) * | 2013-01-11 | 2014-07-17 | Mead Johnson Nutrition Company | Nutritional compositions containing a neurologic component and uses thereof |
US9301966B2 (en) * | 2013-01-11 | 2016-04-05 | Mead Johnson Nutrition Company | Nutritional compositions containing magnesium threonate and uses thereof |
US20150139972A1 (en) * | 2013-11-18 | 2015-05-21 | Gerald Haase | Micronutrient Formulation For Concussive Head Injuries |
WO2015084158A1 (en) * | 2013-12-06 | 2015-06-11 | N.V. Nutricia | A pyrimidine derivative and a fatty acid source for use in the treatment of constipation |
DK3082795T3 (da) * | 2013-12-19 | 2020-08-24 | Tassos Georgiou | Sammensætninger af omega 3 fedtsyrer til behandling af sygdomme, der involverer skader på nervesystemet |
WO2015115885A1 (en) | 2014-01-31 | 2015-08-06 | N.V. Nutricia | Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly |
DE102015101273A1 (de) * | 2015-01-29 | 2016-08-04 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Prophylaxe und Behandlung von frühgeburtlichkeitsassoziierten Entwicklungsstörungen |
WO2016148561A1 (en) | 2015-03-16 | 2016-09-22 | N.V. Nutricia | Method for improving bladder function |
WO2017069613A1 (en) | 2015-10-23 | 2017-04-27 | N.V. Nutricia | Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients |
WO2017069611A1 (en) * | 2015-10-23 | 2017-04-27 | N.V. Nutricia | Nutritional product for decreasing phenylalanine levels in pku patients |
WO2017155387A1 (en) | 2016-03-08 | 2017-09-14 | N.V. Nutricia | Method for supporting memory function and/or cognitive function |
WO2017155386A1 (en) | 2016-03-08 | 2017-09-14 | N.V. Nutricia | Method for treating brain atrophy |
US20190151343A1 (en) * | 2016-04-04 | 2019-05-23 | N.V. Nutricia | Method for improving language skills in children with suspected or confirmed cerebral palsy or children at increased risk thereof |
EP3439647B1 (en) | 2016-04-04 | 2023-03-22 | N.V. Nutricia | Composition for use in reducing or preventing global developmental delay in children |
FI3634396T3 (fi) * | 2017-06-09 | 2023-01-13 | Koostumus L-DOPA-hoidon tehon parantamiseen | |
WO2019013616A1 (en) * | 2017-07-12 | 2019-01-17 | N.V. Nutricia | TREATMENT OF TRAUMATIC BRAIN INJURY |
EP3651749A1 (en) * | 2017-07-12 | 2020-05-20 | N.V. Nutricia | Method for treating traumatic brain injury |
SG11202001131TA (en) * | 2017-08-14 | 2020-03-30 | Axcella Health Inc | Amino acid compositions for the treatment of neuronal injury |
EP3672585A4 (en) * | 2017-08-25 | 2021-06-16 | Struct Nutrition, LLC | COMPOSITIONS AND PROCEDURES FOR THE PREVENTION, RELIEF, AND TREATMENT OF NEUROLOGICAL INJURY AFTER HEAD TRAUMA |
TWI798320B (zh) | 2017-12-21 | 2023-04-11 | 國立大學法人大阪大學 | 神經系統疾患治療劑 |
CN108578367A (zh) * | 2018-06-19 | 2018-09-28 | 吉林百年汉克制药有限公司 | 一种胞二磷胆碱注射液药物组合物及其制备方法和应用 |
KR20220005024A (ko) * | 2019-05-06 | 2022-01-12 | 페레르 인터내쇼날 에스.에이. | 피리미딘 및/또는 퓨린 유도체 및 b 비타민을 포함하는 다층 약제학적 또는 기능 식품용 고체 투여 형태, 이의 제조 및 용도 |
US20230398088A1 (en) * | 2020-10-30 | 2023-12-14 | The Trustees Of The University Of Pennsylvania | Lipid Prophylactic Brain Injury Treatment |
CN117956908A (zh) | 2021-09-17 | 2024-04-30 | N·V·努特里奇亚 | 适合作为营养组合物或补充剂用于患有脑相关障碍、衰退或疾病的动物的固体组合物 |
WO2024003377A1 (en) | 2022-07-01 | 2024-01-04 | N.V. Nutricia | Nutritional composition for stroke |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3734147C2 (de) * | 1987-10-09 | 1998-10-29 | Braun Melsungen Ag | Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung |
WO1989003837A1 (en) * | 1987-10-28 | 1989-05-05 | Pro-Neuron, Inc. | Acylated uridine and cytidine and uses thereof |
US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
US5308832A (en) * | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
US20050203053A1 (en) * | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
AU2634101A (en) * | 2000-01-06 | 2001-07-16 | Martek Biosciences Corporation | Therapeutic preparations of highly unsaturated fatty acids |
AUPQ514600A0 (en) * | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
US6921775B2 (en) * | 2001-08-03 | 2005-07-26 | Children's Medical Center Corporation | Methods for modulating brain damage |
AU2003237379A1 (en) | 2002-06-10 | 2003-12-22 | Oklahoma Medical Research Foundation | A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
AU2005285090A1 (en) * | 2004-09-15 | 2006-03-23 | Massachusetts Institute Of Technology | Compositions containing uridine, and methods utilizing same |
CN101506218A (zh) * | 2005-05-23 | 2009-08-12 | 麻省理工学院 | 含有多不饱和脂肪酸的组合物及其使用方法 |
WO2006127620A2 (en) * | 2005-05-23 | 2006-11-30 | Massachusetts Institute Of Technology | Compositions containing pufa and methods of use thereof |
EP1800675B1 (en) | 2005-12-23 | 2011-05-18 | N.V. Nutricia | Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia |
SG174011A1 (en) * | 2006-04-25 | 2011-09-29 | Children's Medical Ct Corp | Methods and compositions for the treatment of open and closed wound spinal cord injuries |
EP2145637B1 (de) * | 2006-05-09 | 2018-03-07 | Medela Holding AG | Absaugpumpeneinheit |
WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
WO2009002146A1 (en) * | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
PL2194781T5 (pl) | 2007-10-04 | 2021-11-15 | Société des Produits Nestlé S.A. | Kompozycje i sposoby wzmacniania funkcji poznawczych |
CN101896119A (zh) * | 2007-11-02 | 2010-11-24 | 麻省理工学院 | 尿苷饮食添加顺应性方法及其用途 |
WO2011047095A1 (en) * | 2009-10-13 | 2011-04-21 | Martek Biosciences Corporation | Reducing the risk of pathological effects of traumatic brain injury |
-
2011
- 2011-03-14 WO PCT/NL2011/050176 patent/WO2012125020A1/en active Application Filing
-
2012
- 2012-03-14 PL PL12711978T patent/PL2685961T3/pl unknown
- 2012-03-14 EP EP12711978.2A patent/EP2685961B1/en active Active
- 2012-03-14 ES ES12711978.2T patent/ES2687445T3/es active Active
- 2012-03-14 CA CA2830165A patent/CA2830165C/en active Active
- 2012-03-14 EP EP17178922.5A patent/EP3251666A1/en active Pending
- 2012-03-14 RU RU2017119470A patent/RU2749191C2/ru active
- 2012-03-14 BR BR112013023298-6A patent/BR112013023298B1/pt active IP Right Grant
- 2012-03-14 MX MX2013010600A patent/MX355035B/es active IP Right Grant
- 2012-03-14 MX MX2018003636A patent/MX2018003636A/es unknown
- 2012-03-14 RU RU2013145701A patent/RU2622999C2/ru active
- 2012-03-14 US US14/005,098 patent/US9579336B2/en active Active
- 2012-03-14 JP JP2013558806A patent/JP6022488B2/ja active Active
- 2012-03-14 CN CN201710105894.4A patent/CN106902104A/zh active Pending
- 2012-03-14 WO PCT/NL2012/050158 patent/WO2012125034A1/en active Application Filing
- 2012-03-14 CN CN201280023220.5A patent/CN103533921B/zh active Active
- 2012-03-14 BR BR122020000836-9A patent/BR122020000836B1/pt active IP Right Grant
- 2012-03-14 AU AU2012229649A patent/AU2012229649B2/en active Active
-
2016
- 2016-10-05 JP JP2016197308A patent/JP6196359B2/ja active Active
-
2017
- 2017-01-27 US US15/417,943 patent/US10071072B2/en active Active
- 2017-03-15 AU AU2017201766A patent/AU2017201766B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013023298A2 (pt) | uso de uma composição na fabricação de um produto para a prevenção ou tratamento de neurotrauma, lesão cerebral traumática, paralisia cerebral e lesão da coluna vertebral e uso de um kit de partes na fabricação de um produto para a prevenção ou tratamento de neurotrauma, lesão cerebral traumática, paralisia cerebral e lesão da coluna vertebral | |
IL239355A0 (en) | Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders | |
PT2771041T (pt) | Composições e suas utilizações na cicatrização óssea | |
GB2492487B (en) | Cannabinoids for use in the treatment of neurodegenerative diseases or disorders | |
BR112015024846A2 (pt) | composições para utilização no estímulo do crescimento ósseo | |
IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
IL231510B (en) | Preparations for the treatment of bone diseases and broken bones | |
EP2563233A4 (en) | SYSTEM FOR USE IN THE TREATMENT OF VERTEBRAL FRACTURES | |
EP2563232A4 (en) | SYSTEM FOR USE IN THE TREATMENT OF VERTEBRAL FRACTURES | |
ZA201403596B (en) | Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease | |
EP2833883A4 (en) | NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES | |
GB201222455D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease | |
IL236823A0 (en) | Preparations for use in the treatment of bone defects | |
HK1197235A1 (zh) | 二氫吡唑、其藥物組合物及其治療生育障礙的用途 | |
EP3253886A4 (en) | Novel methods for early identification of bone healing ability in injured patients | |
HK1208320A1 (en) | Orthopedic pillow for treatment and prevention of lumbar and thoracic spine diseases | |
BR112013006857A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica e método para o tratamento ou profilaxia de doenças virais | |
HK1206239A1 (en) | Use of composition in preparing health care products or medicines for preventing and treating allergic diseases | |
EP2875820A4 (en) | COMPOSITION AND METHOD FOR PROPHYLAXIS AND TREATMENT OF OSTEOPOROSIS AND BONE BREAKS | |
BRPI0923242A8 (pt) | uso de racematos de pinocembrina na preparacao de medicamentos para tratamento de acidente vascular cerebral | |
HK1206598A1 (en) | Eprotirome for use in the prevention and or treatment of hair disorders and compositions thereof | |
CL2013002100A1 (es) | Compuestos derivados de aminostatina, para aplicacion intraarticular; procedimiento para prepararlos; medicamento; kit farmaceutico; preparacion farmaceutica; procedimiento de obtencion de la preparacion farmaceutica; y uso de esta preparación para tratar o prevenir artrosis y lesiones traumaticas de los cartilagos, entre otras. | |
BR112014028629A2 (pt) | moduladores do receptor de progesterona para o uso na prevenção ou tratamento de doenças mediadas por andrógeno | |
EP2877191A4 (en) | COMPOSITION PRODUCT AND COSMETIC OR MEDICAL COMPOSITION WITH KIGELIA AFRICANA | |
WO2014082738A8 (en) | Heteroquinoline-3-carboxamides as kcnq2/3 modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A23D 7/00 (2006.01), A23D 7/005 (2006.01), A23L 33 |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2012, OBSERVADAS AS CONDICOES LEGAIS. |